Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $20,942.28 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 38,782 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $0.54, for a total value of $20,942.28. Following the transaction, the director directly owned 2,159,860 shares in the company, valued at $1,166,324.40. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total value of $20,577.15.
• On Wednesday, January 14th, Luke Evnin sold 30,616 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total value of $17,451.12.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total transaction of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $11,697.84.

Werewolf Therapeutics Price Performance

HOWL opened at $0.70 on Friday. The stock has a fifty day moving average price of $0.79 and a 200 day moving average price of $1.21. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 1 year low of $0.53 and a 1 year high of $2.38. The stock has a market cap of $33.82 million, a price-to-earnings ratio of -0.43 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Quadrature Capital Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $28,000. Qube Research & Technologies Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth $48,000. AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter worth $79,000. Y Intercept Hong Kong Ltd bought a new position in Werewolf Therapeutics during the second quarter worth $92,000. Finally, Susquehanna International Group LLP raised its stake in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HOWL. Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Wedbush cut shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Friday, December 19th. Bank of America cut their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Finally, Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.